Diethylcarbamazine

CHEMBL684 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
199.3 g/mol
LogP
0.3
Phase
4

An antiparasitic medication used to treat lymphatic filariasis (elephantiasis), loiasis, and tropical pulmonary eosinophilia caused by filarial worms. It works by killing the microfilariae stage of the parasites and immobilizing adult worms, making them susceptible to the immune system. Severe reactions can occur when large numbers of parasites are killed rapidly.

น้ำหนักโมเลกุล

199.2900 g/mol

LogP

0.30

TPSA

26.80 Ų

Lipinski RO5

ผ่าน

กลไกการออกฤทธิ์

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCN(CC)C(=O)N1CCN(C)CC1

InChI

InChI=1S/C10H21N3O/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13/h4-9H2,1-3H3

Molecular Formula

C10H21N3O

HBD / HBA

- / 2

พันธะที่หมุนได้

2

อะตอมหนัก

14

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

An antiparasitic medication used to treat lymphatic filariasis (elephantiasis), loiasis, and tropical pulmonary eosinophilia caused by filarial worms. It works by killing the microfilariae stage of the parasites and immobilizing adult worms, making them susceptible to the immune system. Severe reactions can occur when large numbers of parasites are killed rapidly.

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

Yes, Diethylcarbamazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL684. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3052. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.